Uses machine learning and robotics for multispecific antibody discovery.
| Date | Round | Amount |
|---|---|---|
| May 2024 | Series B LabGenius raised £35M in Series B led by M Ventures (Merck) to advance its AI-powered antibody discovery platform toward clinical trials. | $44M |
| Oct 2020 | Series A London AI drug-discovery startup LabGenius raised an additional $15M in its Series A round led by Atomico. | $15M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.